AMRI, a global contract research, development and manufacturing organization, launched the new multipurpose aseptic API line at the company’s facility in Valladolid, Spain.
The new line was announced in November 2017 and enhances capacity at the site while complementing AMRI’s other aseptic API manufacturing plants in Bon Encontre and Tonneins, France.
This investment – coupled with the build-out of analytical services and a new warehouse, provides additional capacity, technology and expertise to serve customers’ increasing demand for sterile API. It also supports AMRI’s commitment to growth in the region.
AMRI’s lines are designed to meet requirements from pilot-scale to multi-ton scale manufacturing, and the company’s sterilization capability can be integrated with API production or operate as a separate outsourced step for customers who do not have bulk sterile facilities or who may need additional capacity.
AMRI is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded over 22 years ago, AMRI operates in the United States, Europe and Asia, with its headquarters located in Albany, New York.